Bellerophon Therapeutics to Present at Rodman & Renshaw 20th Annual Global Investment Conference
WARREN, N.J., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that Fabian Tenenbaum, Chief Executive Officer, will provide a corporate overview at the Rodman & Renshaw 20th Annual Global Investment Conference, taking place September 4-6, 2018, at the St. Regis New York Hotel.
Bellerophon Presentation Details
Date: Wednesday, September 5
Time: 9:10am Eastern Time
Location: The St. Regis New York Hotel, Fontainebleau Foyer, New York, NY
Webcast: http://wsw.com/webcast/rrshq28/blph/
About Bellerophon
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing multiple product candidates under its INOpulse program, a proprietary pulsatile nitric oxide delivery system. For more information, please visit www.bellerophon.com.
Contact
Bellerophon Therapeutics
Fabian Tenenbaum, Chief Executive Officer
(908) 574-4767
LifeSci Advisors
Brian Ritchie
212-915-2578
britchie@lifesciadvisors.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
